Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Med Sci 2018; 15(13):1547-1554. doi:10.7150/ijms.26329 This issue Cite

Research Paper

Microarray Analysis of Differentially-expressed MicroRNAs in Acquired Middle Ear Cholesteatoma

Shumin Xie1, Xiaoyu Liu2, Zhen Pan2, Xing Chen2, Anquan Peng2, Tuanfang Yin2, Jihao Ren2, Wei Liu2✉

1. Department of Otolaryngology-Head and Neck Surgery, The Xiangya Hospital, Central South University, Hunan provincial key lab, Otolaryngology institute of major diseases, Changsha, Hunan 410008, China.
2. Department of Otolaryngology-Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.

✉ Corresponding author: Wei Liu Address: Department of Otolaryngology-Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China. Telephone: +8613875837130 Fax number: 0731-85295235 E-mail address: liuw More

Citation:
Xie S, Liu X, Pan Z, Chen X, Peng A, Yin T, Ren J, Liu W. Microarray Analysis of Differentially-expressed MicroRNAs in Acquired Middle Ear Cholesteatoma. Int J Med Sci 2018; 15(13):1547-1554. doi:10.7150/ijms.26329. https://www.medsci.org/v15p1547.htm
Other styles

File import instruction

Abstract

Objectives: To analyze the miRNAs expression profiling between acquired middle ear cholesteatoma and normal skin, and to identify several novel miRNAs which may be involved in the etiopathogenesis of middle ear cholesteatoma.

Methods: MiRNA microarray technology was adopted to analyze the miRNA expression profiling between acquired middle ear cholesteatoma and normal skin. qRT-PCR was used to validate selected differentially expressed miRNAs.

Results: The miRNA microarray technology showed totally 44 upregulated (miRNA-21-3p, miRNA-584-5p, miRNA-16-1-3p, etc) and 175 downregulated (miRNA-10a-5p, miRNA-152-5p, miRNA-203b-5p, etc) miRNAs in cholesteatoma tissues with 2-fold change compared with normal skin. The qRT-PCR validation was in accordance with the microarray results partly: miRNA-21-3p and miRNA-16-1-3p expressed significantly higher while miRNA-10a-5p exhibited an obviously decreased expression in middle ear cholesteatoma tissues when compared with normal skin. The GO and KEGG pathway analyses provided clues that these differentially expressed miRNAs might play essential roles in the etiopathogenesis of middle ear cholesteatoma, including cell proliferation, apoptosis, cell cycle, differentiation, bone resorption and remodeling process.

Conclusions: Our study suggests possible roles of differentially expressed miRNAs in the pathogenesis of middle ear cholesteatoma. Targeting on these miRNAs may provide a new strategy for cholesteatoma therapy in the future.

Keywords: miRNA, middle ear, cholesteatoma, etiopathogenesis

Citation styles

APA
Xie, S., Liu, X., Pan, Z., Chen, X., Peng, A., Yin, T., Ren, J., Liu, W. (2018). Microarray Analysis of Differentially-expressed MicroRNAs in Acquired Middle Ear Cholesteatoma. International Journal of Medical Sciences, 15(13), 1547-1554. https://doi.org/10.7150/ijms.26329.

ACS
Xie, S.; Liu, X.; Pan, Z.; Chen, X.; Peng, A.; Yin, T.; Ren, J.; Liu, W. Microarray Analysis of Differentially-expressed MicroRNAs in Acquired Middle Ear Cholesteatoma. Int. J. Med. Sci. 2018, 15 (13), 1547-1554. DOI: 10.7150/ijms.26329.

NLM
Xie S, Liu X, Pan Z, Chen X, Peng A, Yin T, Ren J, Liu W. Microarray Analysis of Differentially-expressed MicroRNAs in Acquired Middle Ear Cholesteatoma. Int J Med Sci 2018; 15(13):1547-1554. doi:10.7150/ijms.26329. https://www.medsci.org/v15p1547.htm

CSE
Xie S, Liu X, Pan Z, Chen X, Peng A, Yin T, Ren J, Liu W. 2018. Microarray Analysis of Differentially-expressed MicroRNAs in Acquired Middle Ear Cholesteatoma. Int J Med Sci. 15(13):1547-1554.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use